/
Infectious Disease
Pneumonia
129
Pipeline Programs↗
129
Active Trials↗
99
Companies Involved↗
Pneumonia is a highly competitive landscape with 129 programs across 99 companies. The most active players are Bristol-Myers Squibb, The Central and Eastern European Gynecologic Oncology Group, KARE Biosciences. 16 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical103
Phase 15
Phase 25
Phase 316
Approved
No programs
Analysis
Modality Breakdown
96%
Small molecule
109 of 113 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 113 classified programs, each share of the total. Modality classified for 98% of 129 pipeline programs.
Analysis
Trial Status
735
clinical trials
Completed378 · 51%
Unknown status128 · 17%
Recruiting66 · 9%
Terminated65 · 9%
Not yet recruiting50 · 7%
Withdrawn33 · 4%
Other15 · 2%
Clinical Trials
Trial Activity
735 trials
Optimizing Care for Children Hospitalized With Community-acquired Pneumonia: a Feasibility Randomized Controlled Trial of a Diagnostic Intervention
Recruiting·—·Preclinical·NCT06114888·75 enrolled
Role of Lactoferrin in Prevention of Ventilator Associated Pneumonia in Neonates.
Recruiting·—·Preclinical·NCT07255742·120 enrolled
Page 1 of 49
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)